← Back to Discover
REGENERON PHARMACEUTICALS, INC.
Period ended Sep 30, 2026 · Latest filing Nov 5, 2026
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Sep 30, 2026: $179,631,814
More quarters will appear as history becomes available.
Top holdings
Top 10 at Sep 30, 2026. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- Parabilis Medicines, Inc. · Common Stock · 698955101 · shares: $134,541,645
- Intellia Therapeutics, Inc. · Common Stock · 45826J105 · shares: $44,658,120
- Adicet Bio, Inc. · Common Stock · 007002207 · shares: $432,049
Reported holdings
3 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| Parabilis Medicines, Inc. | Common Stock | 698955101 | — | 4,166,666 shares | $134,541,645 |
| Intellia Therapeutics, Inc. | Common Stock | 45826J105 | — | 3,702,995 shares | $44,658,120 |
| Adicet Bio, Inc. | Common Stock | 007002207 | — | 60,511 shares | $432,049 |